RBC Sticks to Buy Rating for Eli Lilly & Co Amid Strong Earnings

RBC Capital analyst Trung Huynh has maintained a Buy rating on Eli Lilly & Co (LLY) and set a price target of $1,500.00. This recommendation was made on September 21, with LLY's shares closing at $1,164.89 the previous day.

According to TipRanks, Huynh is a 5-star analyst with an average return of 22.2% and a success rate of 77.18%. His focus is on Healthcare stocks, including Bristol-Myers Squibb, Merck & Company, and Eli Lilly & Co.

In addition to RBC Capital's Buy rating, TD Cowen also recommends buying LLY with a separate report issued on September 22. However, Evercore ISI has taken a more cautious approach, maintaining a Hold rating on the company.